

PEOPLE

Human Genome Sciences (Rockville, MD) has announced the appointment of **Joy A. Cavagnaro** as vice president of regulatory affairs. Dr. Cavagnaro joins Human Genome Sciences from the US Food and Drug Administration (FDA), where she was most recently senior pharmacologist and director of quality assurance at the Center for Biologics Evaluation and Research.

Progenitor Inc. (Menlo Park, CA) has named **Lawrence Cohen** to the newly created position of COO. Mr. Cohen previously served as vice president of research and development at Somatix Therapy Corp.

Pharmos Corp. (Iselin, NJ) has named **Robert Cook** as CFO. Mr. Cook was previously vice president in the health-care group of GE Capital Corp's commercial finance unit.



Stuart M. Essig has been appointed as president and CEO of Integra LifeSciences (Plainsboro, NJ). Mr. Essig was also elected to the company's board of directors. Most recently, he was a managing director at Goldman Sachs, where he supervised the medical technology practice.

Sheffield Pharmaceuticals (St. Louis, MO) has announced that **Thomas M. Fitzgerald** has been appointed chairman of the board of directors, and CEO **Loren G. Peterson** has been appointed to the additional post of president, a position previously held by Mr. Fitzgerald. Mr. Fitzgerald will replace **Douglas R. Eger** as chairman.

GeneMedicine (The Woodlands, TX) has announced the appointment of **Norman Hardman** as senior vice president and COO, a newly created position. Dr. Hardman's previous position with GeneMedicine was senior vice president, discovery and development, and chief scientific officer.

Neogen Corp. (Lansing, MI) has announced that **Joseph Madden** has joined the company as vice president of scientific affairs. Dr. Madden recently retired from his position as microbiology strategic manager in the FDA's Center for Food Safety and Applied Nutrition, and as a captain in the US Public Health Service. He replaces **Brinton Miller**, who assumes the responsibilities of senior vice president for Neogen.

George H. Miller has been appointed senior vice president in charge of research and development at Microcide Pharmaceuticals (Mountain View, CA). Dr. Miller has spent the past 23 years at Schering-Plough Research Institute, most recently as a presidential fellow in infectious disease and microbial products discovery.

Elan Corp. (Dublin, Ireland) has announced the appointment of **Mary K. Pendergast** to the newly created position of executive vice president, government affairs. She joins Elan from the FDA, where she was deputy commissioner and senior advisor to the commissioner.

Phogen (Cambridge, UK) has announced the appointment of **Sir Mark Henry Richmond** to its board of directors. Dr. Richmond currently serves as a nonexecutive director at Cancer Research Campaign Technology. He also acts as a science advisor to Rothschild Asset Management Ltd.

Centocor, Inc. (Malvern, PA) has appointed **Joseph C. Scodari** president and COO and **Dominic J. Caruso** senior vice president and CFO. As president, Scodari succeeds **David P. Holveck**, who continues as CEO. Mr. Scodari joined Centocor in April 1996 from Rhône-Poulenc Rorer Pharmaceuticals. Mr. Caruso joined Centocor in 1985. The company has also appointed **Christopher C. Hentschel** as senior vice president and chief scientific officer. For the past 10 years, Dr. Hentschel has served as the CEO and scientific director for the United Kingdom's Medical Research Council Collaborative Center.

Barry M. Sherman has been elected to the board of directors of Celtrix Pharmaceuticals (Santa Clara, CA). Dr. Sherman is president and CEO of Anergex, and also a clinical professor of internal medicine at Stanford University.

Former US Senator **Alan K. Simpson** has been elected to the board of directors of Biogen (Cambridge, MA). Senator Simpson retired from Congress in January 1997 as the senior senator from Wyoming after 18 years in the US Senate. He is currently a visiting lecturer at the Shorenstein Center on the Press, Politics, and Public Policy at the John F. Kennedy School of Government of Harvard University.

Robert Strauss has been named CEO and president of Noven Pharmaceuticals (Miami, FL). He succeeds **Steven Sablowsky**, who will remain as chairman. Mr. Strauss most

recently served as president and COO of IVAX Corp.

Vertex Pharmaceuticals (Cambridge, MA) has named **Elaine S. Ullian** to the board of directors. Ms. Ullian is president and CEO of Boston Medical Center, a private, nonprofit academic medical center specializing in cardiovascular medicine, trauma, cancer, Parkinson's Disease, arthritis, and infectious diseases.

Cephalon, Inc. (West Chester, PA) has announced the appointments of **Jeffrey Vaught** to the position of president, research and development division; **Peter Grebow** to senior vice president, worldwide business development; and **Efraim Shek** to vice president, drug development. Dr. Vaught joined Cephalon in 1991 as vice president of research, and was promoted to senior vice president of research in 1994. Dr. Grebow joined Cephalon in 1991 as director of drug development and became senior vice president of drug development in 1994. Dr. Shek joined Cephalon in 1994 as vice president of pharmaceuticals and analytical chemistry.

Visit the nature family on the world wide web at:
<http://www.nature.com>

or access each sister journal directly:

nature
biotechnology

<http://www.biotech.nature.com>

nature
genetics

<http://www.genetics.nature.com>

nature
medicine

<http://www.medicine.nature.com>

nature
structural
biology

<http://www.structbio.nature.com>